SamanTree Medical, a trailblazer in medical technology focusing on enhancing surgical outcomes, has successfully closed a $14 million Series B funding round. The capital infusion, spearheaded by Relyens Innovation Santé and advised by Turenne Capital, marks a pivotal moment for the company as it accelerates its mission to advance the field of surgical imaging.
The highlight of this funding round is the bolstering of SamanTree’s flagship product, the Histolog® Scanner. This CE-marked device revolutionizes surgical practices by offering real-time, high-resolution imaging of fresh tissue surfaces during operations. Unlike conventional methods, the Histolog® Scanner leverages ultra-fast confocal microscopy to enable pathologists and surgeons to make critical intra-operative decisions swiftly and accurately.
Claire Poulard, Investment Director at Turenne Capital, commented on the significance of the Histolog® Scanner: “SamanTree Medical has demonstrated remarkable potential with its Histolog® Scanner, showing promise in enhancing surgical precision across various soft-tissue procedures. We are eager to collaborate with SamanTree to expand the reach of this transformative technology globally.”
The financing round also welcomes new strategic investors Mutuelles Impact, Wille Finance, Noshaq, and WE Life Sciences (Wallonie Entreprendre), alongside returning supporters Panakès Partners, BOM, and b2venture. This diversified backing underscores confidence in SamanTree Medical’s strategic vision and technological prowess.
Joining the Board of Directors are Claire Poulard and Henry Charlton, SVP and Chief Commercial Officer at Intuitive, reflecting the company’s commitment to leveraging extensive industry expertise in driving commercialization and market penetration efforts.
Olivier Delporte, CEO of SamanTree Medical, expressed gratitude for the support: “This funding round, coupled with the strategic additions to our board, positions SamanTree Medical to accelerate innovation, expand globally, and enhance our digital solutions. We are poised to make significant strides in advancing surgical care and improving patient outcomes.”
SamanTree Medical plans to use the funding to establish its operational base in Wallonia, Belgium, while maintaining its R&D hub in Lausanne, Switzerland. The company aims to scale commercial operations across Europe and anticipates entering the US market by the end of 2024, pending regulatory approvals from the FDA.
As the company continues its trajectory of growth and innovation, SamanTree Medical remains dedicated to pioneering advancements in surgical imaging technology that promise to redefine standards in surgical precision and patient care.
Editorial Opinion:
SamanTree Medical’s strategic focus on enhancing surgical precision through advanced imaging technology places it at the forefront of innovation in the medical field. With the Histolog® Scanner poised to revolutionize intra-operative assessments, the company is well-positioned to meet the rising demand for sophisticated medical solutions that improve patient outcomes. By expanding its global footprint and enhancing digital capabilities, SamanTree Medical is setting a precedent for how technology can profoundly impact surgical practices, underscoring its potential to shape the future of healthcare.
If you need further assistance or have any corrections, please reach out to editor@thetimesmag.com.
